Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jul;29(7):1564-70.
doi: 10.1038/leu.2015.43. Epub 2015 Feb 17.

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma

Affiliations
Comparative Study

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma

H Horn et al. Leukemia. 2015 Jul.

Abstract

Prognostically relevant risk factors in patients with diffuse large B-cell lymphoma (DLBCL) have predominantly been evaluated in elderly populations. We tested whether previously described risk factors are also valid in younger, poor-prognosis DLBCL patients. Paraffin-embedded samples from 112 patients with de novo DLBCL, enrolled in the R-MegaCHOEP trial of the German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) were investigated using immunohistochemistry (MYC, FOXP1, LMO2, GCET1, CD5, CD10, BCL2, BCL6, IRF4/MUM1) and fluorescence in situ hybridization (MYC, BCL2, BCL6). MYC, BCL2 and BCL6 breaks occurred in 14, 21 and 31%, respectively. In the majority of cases, MYC was simultaneously rearranged with BCL2 and/or BCL6. The adverse impact of MYC rearrangements was confirmed, but the sole presence of BCL2 breaks emerged as a novel prognostic marker associated with inferior overall survival (OS) (P=0.002). Combined overexpression of MYC and BCL2 showed only limited association with inferior OS. All immunohistochemical cell of origin classifiers applied failed to predict survival time. DLBCL tumors with significant proportion of immunoblastic and/or immunoblastic-plasmacytoid cells had inferior OS, independently from from BCL2 break. Younger, poor-prognosis DLBCL patients, therefore, display different biological risk factors compared with an elderly population, with BCL2 translocations emerging as a powerful negative prognostic marker.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Haematologica. 2013 Oct;98(10):1554-62 - PubMed
    1. Blood. 2004 Jan 1;103(1):275-82 - PubMed
    1. J Clin Oncol. 2012 Oct 1;30(28):3452-9 - PubMed
    1. J Clin Oncol. 2009 Nov 20;27(33):5573-9 - PubMed
    1. Lancet Oncol. 2012 Dec;13(12):1250-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources